HMG improves IVF outcome in patients with high basal FSH/LH ratio: A preliminary study

Reproductive BioMedicine Online

Volumn 18, Issue 2, 2009, Pages 205-208

  Orvieto, Raoul ^a,b   Homburg, Roy ^a   Meltcer, Simion ^a   Rabinson, Jacob ^a   Anteby, Eyal Y ^a,b   Nahum, Ravit ^a  

^a BARZILAI MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

HMG; IVF outcome; LH ratio; Ovarian stimulation; Pregnancy; RFSH

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HUMAN; INFERTILITY; LUTEINIZING HORMONE BLOOD LEVEL; NIDATION; OVULATION INDUCTION; PREGNANCY OUTCOME; PREGNANCY RATE;

EID: 60549095143     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60257-X     Document Type: Article

References (24)

1. Al-Inany HG, Abou-Setta AM, Aboulghar NM et al. 2008 Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reproductive BioMedicine Online 16, 81-88.
2. Barroso G, Oehninger S, Monzo A et al. 2001 High FSH:LH ratio and low LH levels in basal cycle day 3: impact on follicular development and IVF outcome. Journal of Assisted Reproduction and Genetics 18, 499-505.
3. Bentick B, Shaw RW, Iffland CA et al. 1988 A randomised comparative study of purified follicle-stimulating hormone and human menopausal gonadotropin after pituitary desensitisation with Buserelin for superovulation and in-vitro fertilisation. Fertility and Sterility 50, 79-84.
4. Broekmans FJ, Kwee J, Hendriks DJ et al. 2006 A systematic review of tests predicting ovarian reserve and IVF outcome. Human Reproduction Update 12, 685-718.
5. Coomarasamy A, Afnan M, Cheema D et al. 2008 Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Human Reproduction 23, 310-315.
6. Daya S, Gunby J, Hughes EG et al. 1995 Follicle stimulating hormone versus human menopausal gonadotropin for in-vitro fertilization cycles: a meta-analysis. Fertility and Sterility 64, 347-354.
7. Gomez-Palomares JL, Acevedo-Martin B, Andres L et al. 2005 LH improves early follicular recruitment in women over 38 years old. Reproductive BioMedicine Online 11, 409-414.
8. Hillier SG 2000 Controlled ovarian stimulation in women. Journal of Reproduction and Fertility 120, 201-210.
9. Kolibianakis EM, Kalogeropoulou L, Griesinger G et al. 2007 Among patients treated with FSH and GnRH analogues for in-vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Human Reproduction Update 13, 445-452.
10. Martin-Johnston M, Beltsos AN, Grotjan HE, Uhler ML 2007 Adding human menopausal gonadotrophin to antagonist protocols - is there a benefit? Reproductive BioMedicine Online 15, 161-168.
11. Mochtar MH, Van der Veen F, Ziech M et al. 2007 Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews 2, CD005070.
12. Muasher SJ, Abdallah RT, Hubayter ZR 2006 Optimal stimulation protocols for in-vitro fertilization. Fertility and Sterility 86, 267-273.
13. Mukherjee T, Copperman AB, Lapinski R et al. 1996 An elevated day three follicle-stimulating hormone: luteinizing hormone ratio (FSH:LH) in the presence of a normal day 3 FSH predicts a poor response to controlled ovarian hyperstimulation. Fertility and Sterility 65, 588-593.
14. Noci I, Maggi M, Fuzzi B et al. 2000 Effects of low day 3 luteinizing hormone levels on in-vitro fertilization treatment outcome. Gynecological Endocrinology 14, 321-326.
15. Noci I, Biagiotti R, Maggi M et al. 1998 Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation. Human Reproduction 13, 531-534.
16. Orvieto R, Meltcer S, Rabinson J et al. 2008 Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH-analogues? Fertility and Sterility 90, 1297-300.
17. Out HJ, Driessen SG, Mannaerts BM et al. 1997 Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in-vitro fertilization than urinary gonadotropins. Fertility and Sterility 68, 138-142.
18. Penarrubia J, Fabregues F, Creus M et al. 2003 LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. Human Reproduction 18, 2689-2697.
19. Penzias AS 2004 Improving results with assisted reproductive technologies: individualized patient-tailored strategies for ovulation induction. Reproductive BioMedicine Online 9, 43-46.
20. Platteau P, Smitz J, Albano C et al. 2004 Exogenous luteinizing hormone activity may influence the treatment outcome in in-vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertility and Sterility 81, 1401-1404.
21. Shrim A, Elizur SE, Seidman DS et al. 2006 Elevated day 3 FSH/LH ratio due to low LH concentrations predicts reduced ovarian response. Reproductive BioMedicine Online 12, 418-422.
22. Taymor ML 1996 The regulation of follicle growth: some clinical implications in reproductive endocrinology. Fertility and Sterility 65, 235-247.
23. Van Wely M, Westergaard LG, Bossuyt PM et al. 2003 Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews 1, CD003973.
24. Ziebe S, Lundin K, Janssens R et al. 2007 Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Human Reproduction 22, 2404-2413.